Literature DB >> 35201849

A Case of Prostate Cancer Harboring Androgen Receptor T878A Progesterone-Responsive Mutant Emerging After Abiraterone Acetate Treatment Responding to Darolutamide.

Andreas Varkaris1, Julia Stevens1, Yuho Ono2, Steven P Balk1, Joaquim Bellmunt1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35201849      PMCID： PMC8974572          DOI： 10.1200/PO.21.00091

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  6 in total

1.  Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Authors:  Mary-Ellen Taplin; Bruce Montgomery; Christopher J Logothetis; Glenn J Bubley; Jerome P Richie; Bruce L Dalkin; Martin G Sanda; John W Davis; Massimo Loda; Lawrence D True; Patricia Troncoso; Huihui Ye; Rosina T Lis; Brett T Marck; Alvin M Matsumoto; Steven P Balk; Elahe A Mostaghel; Trevor M Penning; Peter S Nelson; Wanling Xie; Zhenyang Jiang; Christopher M Haqq; Daniel Tamae; NamPhuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Philip W Kantoff
Journal:  J Clin Oncol       Date:  2014-10-13       Impact factor: 44.544

2.  Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors.

Authors:  Eddy J Chen; Adam G Sowalsky; Shuai Gao; Changmeng Cai; Olga Voznesensky; Rachel Schaefer; Massimo Loda; Lawrence D True; Huihui Ye; Patricia Troncoso; Rosina L Lis; Philip W Kantoff; Robert B Montgomery; Peter S Nelson; Glenn J Bubley; Steven P Balk; Mary-Ellen Taplin
Journal:  Clin Cancer Res       Date:  2014-10-15       Impact factor: 12.531

3.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.

Authors:  M E Taplin; G J Bubley; T D Shuster; M E Frantz; A E Spooner; G K Ogata; H N Keer; S P Balk
Journal:  N Engl J Med       Date:  1995-05-25       Impact factor: 91.245

4.  Plasma AR and abiraterone-resistant prostate cancer.

Authors:  Alessandro Romanel; Delila Gasi Tandefelt; Vincenza Conteduca; Anuradha Jayaram; Nicola Casiraghi; Daniel Wetterskog; Samanta Salvi; Dino Amadori; Zafeiris Zafeiriou; Pasquale Rescigno; Diletta Bianchini; Giorgia Gurioli; Valentina Casadio; Suzanne Carreira; Jane Goodall; Anna Wingate; Roberta Ferraldeschi; Nina Tunariu; Penny Flohr; Ugo De Giorgi; Johann S de Bono; Francesca Demichelis; Gerhardt Attard
Journal:  Sci Transl Med       Date:  2015-11-04       Impact factor: 17.956

5.  Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.

Authors:  Rana R McKay; Lucia Kwak; Jett P Crowdis; Jamie M Sperger; Shuang G Zhao; Wanling Xie; Lillian Werner; Rosina T Lis; Zhenwei Zhang; Xiao X Wei; Joshua M Lang; Eliezer M Van Allen; Rupal S Bhatt; Evan Y Yu; Peter S Nelson; Glenn J Bubley; R Bruce Montgomery; Mary-Ellen Taplin
Journal:  Clin Cancer Res       Date:  2021-04-13       Impact factor: 12.531

6.  Genomic correlates of clinical outcome in advanced prostate cancer.

Authors:  Wassim Abida; Joanna Cyrta; Glenn Heller; Davide Prandi; Joshua Armenia; Ilsa Coleman; Marcin Cieslik; Matteo Benelli; Dan Robinson; Eliezer M Van Allen; Andrea Sboner; Tarcisio Fedrizzi; Juan Miguel Mosquera; Brian D Robinson; Navonil De Sarkar; Lakshmi P Kunju; Scott Tomlins; Yi Mi Wu; Daniel Nava Rodrigues; Massimo Loda; Anuradha Gopalan; Victor E Reuter; Colin C Pritchard; Joaquin Mateo; Diletta Bianchini; Susana Miranda; Suzanne Carreira; Pasquale Rescigno; Julie Filipenko; Jacob Vinson; Robert B Montgomery; Himisha Beltran; Elisabeth I Heath; Howard I Scher; Philip W Kantoff; Mary-Ellen Taplin; Nikolaus Schultz; Johann S deBono; Francesca Demichelis; Peter S Nelson; Mark A Rubin; Arul M Chinnaiyan; Charles L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-06       Impact factor: 11.205
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.